Effects of Long-term Treatment with Simvastatin on Plasma Lipids and Lipoproteins in Patients with Primary Hypercholesterolemia

Overview

Journal Klin Wochenschr

Specialty General Medicine

Date 1990 Aug 17

PMID 2214604

Citations 3

Authors

J Thiery

C Creutzfeldt

W Creutzfeldt

A K Walli

D Seidel

Affiliations

Soon will be listed here.

Abstract

We investigated long-term hypolipidemic effects and clinical safety of simvastatin, a new competitive inhibitor of 3-hydroxy-methylglutaryl coenzyme A reductase in 24 patients with familial and non-familial hypercholesterolemia. Patients received up to 40 mg simvastatin for a period of 30 months. Significant decreases were noted in plasma cholesterol (30%), plasma triglycerides (25%), very low density lipoprotein-cholesterol (26%), and low density lipoprotein-cholesterol (40%), whereas an increase in plasma high density lipoprotein-cholesterol (11%) was observed. Furthermore, the percentage decrease in plasma low density lipoprotein cholesterol was independent of individual baseline concentrations. Simvastatin did not alter the composition of low density lipoproteins or high density lipoproteins. The percentage decrease in total plasma and low density lipoprotein-cholesterol was independent of apoprotein E isoforms and low density lipoprotein-receptor activity as assayed in cultured fibroblasts. The drug therapy was well tolerated and clinical examinations revealed no adverse effects. Clinical chemistry indices and hematological, as well as endocrinological parameters remained within normal limits and ranges.

Citing Articles

LDL-apheresis: technical and clinical aspects.

Bambauer R, Bambauer C, Lehmann B, Latza R, Schiel R ScientificWorldJournal. 2012; 2012:314283.

PMID: 22654591 PMC: 3361163. DOI: 10.1100/2012/314283.

Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Chrisp P, Lewis N, Milne R Pharmacoeconomics. 1992; 1(2):124-45.

PMID: 10146941 DOI: 10.2165/00019053-199201020-00009.

Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.

Crook D, Bruce R, Worthington M, Mulcahy D, Patterson D, WYNN V Cardiovasc Drugs Ther. 1992; 6(6):633-9.

PMID: 1292582 DOI: 10.1007/BF00052565.

References

Mahley R, Innerarity T . Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta. 1983; 737(2):197-222. DOI: 10.1016/0304-4157(83)90001-1. View

Endo A, Kuroda M, Tsujita Y . ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976; 29(12):1346-8. DOI: 10.7164/antibiotics.29.1346. View

Warnick G, Mayfield C, Albers J, Hazzard W . Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3. Clin Chem. 1979; 25(2):279-84. View

Vega G, East C, Grundy S . Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis. 1988; 70(1-2):131-43. DOI: 10.1016/0021-9150(88)90107-4. View

Farnsworth W, Hoeg J, Maher M, Brittain E, Sherins R, BREWER Jr H . Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. J Clin Endocrinol Metab. 1987; 65(3):546-50. DOI: 10.1210/jcem-65-3-546. View

Tobert J . New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation. 1987; 76(3):534-8. DOI: 10.1161/01.cir.76.3.534. View

Hoeg J, BREWER Jr H . 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA. 1987; 258(24):3532-6. View

Grundy S . Cholesterol and coronary heart disease. A new era. JAMA. 1986; 256(20):2849-58. View

Wieland H, Cremer P, Seidel D . Determination of apolipoprotein B by kinetic (rate) nephelometry. J Lipid Res. 1982; 23(6):893-902. View

10.

Allen J, Thompson G, MYANT N . Normal adrenocortical response to adrenocorticotrophic hormone in patients with homozygous familial hypercholesterolaemia. Clin Sci (Lond). 1983; 65(1):99-101. DOI: 10.1042/cs0650099. View

11.

Frishman W, Rapier R . Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989; 73(2):437-48. DOI: 10.1016/s0025-7125(16)30681-2. View

12.

Witztum J, Young S, Elam R, Carew T, Fisher M . Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I. Studies in the guinea pig. J Lipid Res. 1985; 26(1):92-103. View

13.

Norman D, Illingworth D, Munson J, Hosenpud J . Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988; 318(1):46-7. DOI: 10.1056/NEJM198801073180110. View

14.

Behrens-Baumann W, Morawietz A, Thiery J, Creutzfeldt C, Seidel D . Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up. Lens Eye Toxic Res. 1989; 6(1-2):331-7. View

15.

HAVEL R, Hunninghake D, Illingworth D, Lees R, Stein E, Tobert J . Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med. 1987; 107(5):609-15. DOI: 10.7326/0003-4819-107-5-609. View

16.

Ma P, Gil G, Sudhof T, Bilheimer D, Goldstein J, Brown M . Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A. 1986; 83(21):8370-4. PMC: 386930. DOI: 10.1073/pnas.83.21.8370. View

17.

Burstein M, Scholnick H, Morfin R . Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970; 11(6):583-95. View

18.

Armstrong V, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T . Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest. 1989; 19(3):235-40. DOI: 10.1111/j.1365-2362.1989.tb00223.x. View

19.

Walli A, Seidel D . Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat. J Clin Invest. 1984; 74(3):867-79. PMC: 425242. DOI: 10.1172/JCI111504. View

20.

ALBERTS A, Chen J, Kuron G, Hunt V, Huff J, Hoffman C . Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980; 77(7):3957-61. PMC: 349746. DOI: 10.1073/pnas.77.7.3957. View